Company
Investment-firm
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Contacts
location
Contact Email
Website URL
Similar Companies1000
Lux Capital
Lux Capital is an investment firm that invests in counter-conventional early-stage science and tech ventures.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
2050 Capital
2050 Capital is an early-stage deep technology and science investment organization.
Sector
Subsector
Keywords
Location
count Of Investments
Envirtue Capital LLC
Envirtue Capital is a global investment firm that focuses on hi-tech opportunities that have the potential to change the world.
Sector
Subsector
Keywords
Location
Dasein Capital
Dasein Capital is a New York-based venture capital firm that invests seed-stage capital and offers a community-based incubator framework.
Sector
Subsector
Keywords
Location
count Of Investments
Financials
Investments27
Mentee Robotics
Mentee Robotics combines robotics, sensing, and artificial intelligence to create a humanoid robot.
total rounds
total raised
Sunfire
Sunfire is an electrolysis company that designs and manufactures systems for renewable industrial gas and fuel production.
Sector
Subsector
Keywords
Location
total rounds
total raised
Nu Quantum
Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Exits1
6D.ai
6D.ai develops APIs for the AR Cloud.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders7
Zoubin Gharamani
Zoubin Ghahramani is a Professor at the University of Cambridge and Chief Scientist at Uber. He is also Deputy Director of the Leverhulme Centre for the Future of Intelligence, Fellow of the Royal Society and of St John's College, a founding Director of the Alan Turing Institute and co-founder of Geometric Intelligence.
current job
count Of Investments
Zoubin Gharamani
Martin Rees
Lord Martin Rees is a world-renowned astrophysicist, Astronomer Royal, founder of CSER, former President of the Royal Society and former Master of Trinity College, University of Cambridge. Lord Martin Rees is a world-leading cosmologist and astrophysicist. He has been Astronomer Royal since 1995 and was Master of Trinity College, Cambridge from 2004 to 2012 and President of the Royal Society between 2005 and 2010. Lord Rees is the author of more than 500 research papers, and he has made important contributions to the origin of cosmic microwave background radiation, as well as to galaxy clustering and formation. His studies of the distribution of quasars led to final disproof of Steady State theory. In addition to his scientific interests, Lord Rees has written and spoken extensively about the interfaces between science, ethics and politics. He is a member of the Board of the Institute for Advanced Study in Princeton, the Oxford Martin School and the Gates Cambridge Trust. He co-founded the Centre for the Study of Existential Risk and serves on the Scientific Advisory Board for the Future of Life Institute.
current job
organization founded
Martin Rees
Shankar Balasubramian
Professor Sir Shankar Balasubramanian, Co-founder of Cambridge Epigenetix and pioneering researcher, shares his perspectives on Chairing the company’s Scientific Advisory Board (SAB), his research and the opportunities that lay ahead in the field of epigenetics.
current job
organization founded
Shankar Balasubramian
Gregory Winter
Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge. Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale. Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.
current job
count Of Investments
Gregory Winter
Employee Profiles12
Activity
Recent News5
The graph reveals the ratio (%) of positive news articles in a chosen time range